dlt446 dlt446

dlt446 dlt446

Clinical Professor

Member of:

  • Neurology


  1. 2023
  2. Published

    Migraine aura-like episodes following sclerotherapy for varicose veins of the lower extremities — A systematic review

    Bahtiri, L., Thomsen, A. V., dlt446, dlt446 & Hougaard, A., 2023, In: Headache. 63, 1, p. 40-50 11 p.

    Research output: Contribution to journalReviewResearchpeer-review

  3. Published

    Migraine in older adults

    Hugger, S. S., Do, T. P., Ashina, H., Goicochea, M. T., Jenkins, B., Sacco, S., Lee, M. J., Brennan, K. C., Amin, Faisal Mohammad, Steiner, Timothy & dlt446, dlt446, 2023, In: The Lancet Neurology. 22, 10, p. 934-945 12 p.

    Research output: Contribution to journalReviewResearchpeer-review

  4. Published

    Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis

    dlt446, dlt446, Mitsikostas, D. D., Ramirez Campos, V., Barash, S., Ning, X. & Diener, H. C., 2023, In: Headache. 63, 10, p. 1351-1358

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial

    dlt446, dlt446, Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M. & Trugman, J. M., 2023, In: Headache. 63, 1, p. 79-88 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial

    Lipton, R. B., Halker Singh, R. B., Mechtler, L., McVige, J., Ma, J., Yu, S. Y., Stokes, J., Dabruzzo, B., Gandhi, P. & dlt446, dlt446, 2023, In: Cephalalgia. 43, 9, p. 1-10

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies

    de Boer, I., Verhagen, I. E., Souza, M. N. P. & dlt446, dlt446, 2023, In: Cephalalgia. 43, 2, p. 1-13

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    Placebo and nocebo in the treatment of migraine: How much does real world effectiveness depend on contextual effects?

    Basedau, H., Ornello, R., Matteis, E. D., Davaasuren, B., Kadyrova, B., Vuralli, D., Bozhenko, M., Azizova, I., Bitsadze, N., Eralieva, E., dlt446, dlt446, Mitsikostas, D. & Puledda, F., 2023, In: Cephalalgia. 43, 12, p. 1-12

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    Plasma levels of VIP are not elevated during PACAP- and VIP-induced cluster headache attacks: an exploratory study

    Deligianni, C., Pellesi, L., Chaudhry, B. A., Haulund Vollesen, A. L., Snoer, A. H., Hannibal, Jens, Jensen, Rigmor Højland & dlt446, dlt446, 2023, In: Frontiers in Neurology. 14, 8 p., 1135246.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Prolactin in headache and migraine: A systematic review of clinical studies

    Al-Karagholi, M. A. M., Kalatharan, V., Ghanizada, Hashmat, Gram, C., Dussor, G. & dlt446, dlt446, 2023, In: Cephalalgia. 43, 2, 19 p.

    Research output: Contribution to journalReviewResearchpeer-review

  11. Published

    Prolactin in headache and migraine: A systematic review of preclinical studies

    Al-Karagholi, M. A. M., Kalatharan, V., Ghanizada, Hashmat, Dussor, G. & dlt446, dlt446, 2023, In: Headache. 63, 5, p. 577-584 8 p.

    Research output: Contribution to journalReviewResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...38 Next

ID: 920785